文献速递白血病

在实验室间研究中评估急性髓系白血病分子可测量残留病检测

Assessment of acute myeloid leukemia molecular measurable residual disease testing in an interlaboratory study.
PubMed 文献 · Blood Adv · 2023-01-01

欧洲白血病网(ELN)可测量残留病(MRD)工作组已发布共识指南,用于标准化 t(8;21)(q22;q22.1) RUNX1::RUNX1T1、inv(16)(p13.1q22) CBFB::MYH11、t(15;17)(q24.1;q21.2) PML::RARA 和 NPM1 A 型标志的分子遗传学 MRD 检测。一项涉及 29 个国际实验室的研究评估了检测及结果解读的实验室间差异。多数参与者能准确检测、定量并正确解读 MRD 结果,但少数错误在临床中会导致患者结局误分类和不恰当治疗路径;NPM1 标志阴性样本中高比例参与者报告假阳性。

要点

  • 多数参与实验室能达到临床试验或标准诊疗所预期的熟练水平。
  • NPM1 标志阴性样本中高比例参与者报告假阳性结果。
  • 多数错误与结果解读相关,ELN 指南对某些临床场景缺乏清晰度。

核心结论

  • 多数参与者能准确检测、定量并正确解读 MRD 检测结果,达到临床试验或标准诊疗所预期的熟练水平。
  • 少数检测和解读错误在患者场景中会导致患者结局误分类和不恰当治疗路径。
  • NPM1 标志阴性样本中高比例参与者报告假阳性结果,可能使患者接受不必要的额外化疗和/或移植。
  • 研究发现的多数错误与结果解读相关,ELN 指南对某些临床场景缺乏清晰度,需紧急修订指南并开展相关教育。

研究设计与样本

  • 一项涉及 29 个国际实验室的实验室间研究,评估 MRD 检测及结果解读的实验室间差异。

主要发现

  • 多数参与者能检测、准确定量并正确解读 MRD 检测结果。
  • 少数检测和解读错误在患者场景中会导致结局误分类和不恰当治疗路径。
  • NPM1 标志阴性样本中高比例参与者报告假阳性结果。
  • 研究发现的多数错误与结果解读相关。

关键数值与推荐

  • ELN MRD 工作组已发布共识指南,标准化 t(8;21)(q22;q22.1) RUNX1::RUNX1T1、inv(16)(p13.1q22) CBFB::MYH11、t(15;17)(q24.1;q21.2) PML::RARA 和 NPM1 A 型标志的分子遗传学 MRD 检测。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文指出 ELN 指南对某些临床场景缺乏清晰度。
  • 原文强调需要在该领域持续开展外部质量评估/熟练度检测。
  • 原文指出需要紧急修订指南以阐明这些问题,并围绕修订开展相关教育以确保有效传播。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The European LeukaemiaNet (ELN) measurable residual disease (MRD) working group has published consensus guidelines to standardize molecular genetic MRD testing of the t(8;21)(q22;q22.1) RUNX1::RUNX1T1, inv(16)(p13.1q22) CBFB::MYH11, t(15;17)(q24.1;q21.2) PML::RARA, and NPM1 type A markers. A study featuring 29 international laboratories was performed to assess interlaboratory variation in testing and the subsequent interpretation of results, both crucial to patient safety. Most participants in this study were able to detect, accurately quantify, and correctly interpret MRD testing results, with a level of proficiency expected from a clinical trial or standard-of-care setting. However, a few testing and interpretive errors were identified that, in a patient setting, would have led to misclassification of patient outcomes and inappropriate treatment pathways being followed. Of note, a high proportion of participants reported false-positive results in the NPM1 marker-negative sample. False-positive results may have clinical consequences, committing patients to unneeded additional chemotherapy and/or transplant with the attendant risk of morbidity and mortality, which therefore highlights the need for ongoing external quality assessment/proficiency testing in this area. Most errors identified in the study were related to the interpretation of results. It was noted that the ELN guidance lacks clarity for certain clinical scenarios and highlights the requirement for urgent revision of the guidelines to elucidate these issues and related educational efforts around the revisions to ensure effective dissemination.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Scott S, Dillon R, Thiede C, et al. Assessment of acute myeloid leukemia molecular measurable residual disease testing in an interlaboratory study. Blood Adv. 2023. PMID: 36939402. doi:10.1182/bloodadvances.2022009379

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。